Sutro Biopharma has been granted a patent for hemiasterlin derivatives, conjugates, and compositions for treating cell proliferation and cancer. The compounds, including those in Formula 1000, offer methods for treatment, prevention, detection, and diagnosis of cell proliferation and cancer. GlobalData’s report on Sutro Biopharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Sutro Biopharma, Nanoparticle drug conjugates was a key innovation area identified from patents. Sutro Biopharma's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Compound according to formula 1000 for cancer treatment
See Also:
A recently granted patent (Publication Number: US11866515B2) discloses a compound represented by Formula 1000, along with its various derivatives and forms. The compound, along with its pharmaceutically acceptable salts or tautomers, is characterized by the presence of a divalent five- or six-membered monocyclic heteroaryl, a six-membered monocyclic aryl, or a ten-membered fused bicyclic aryl, among other variations.
Furthermore, the patent covers the use of the compound in pharmaceutical compositions, where it can be combined with pharmaceutically acceptable excipients, carriers, or diluents. The composition can be formulated to include the compound with specific characteristics, as outlined in the claims, to enhance its efficacy and bioavailability for potential therapeutic applications. This patent provides a detailed framework for the synthesis, formulation, and potential uses of the compound in the field of pharmaceuticals, paving the way for further research and development in this area.
To know more about GlobalData’s detailed insights on Sutro Biopharma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
